Intercept Pharmaceuticals, a biopharmaceutical firm, is focused on the commercialization and development of therapeutics to treat non-viral and progressive liver diseases. The company was founded in 2002 and is headquartered in New York, New York. Additional operations are located across the United States, Canada, Europe, and Australia.

Intercept Pharmaceuticals’ work focuses on research aimed to remedy primary biliary cholangitis and other liver diseases. Its lead product is called OCALIVA®, for the healing of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid or as treatment for adults unable to accept UDCA. This drug is the first treatment of PBC that targets the farnesoid X receptor, a key regulator of inflammatory, bile acid, metabolic, and fibrotic pathways. In addition, Intercept launched a comprehensive patient support program called Interconnect®, which provides custom support through care coordinators to patients requiring treatment support, disease education, and financial assistance options.

The team at Intercept Pharmaceuticals is comprised of dedicated, smart, hard-working professionals eager to achieve meaningful success, and the company is always looking to hire top talent. Benefits offered to eligible employees include insurance options, competitive pay, family support, retirement benefits, tuition reimbursement, and commuter benefits. Full-time, telecommute positions are offered to qualified candidates seeking work flexibility.

Intercept Pharmaceuticals, a biopharmaceutical firm, is focused on the commercialization and development of therapeutics to treat non-viral and progressive liver diseases. The company was founded in 2002 and is headquartered in New York, New York. Additional operations are located across the United States, Canada, Europe, and Australia.

Intercept Pharmaceuticals’ work focuses on research aimed to remedy primary biliary cholangitis and other liver diseases. Its lead product is called OCALIVA®, for the healing of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid or as treatment for adults unable to accept UDCA. This drug is the first treatment of PBC that targets the farnesoid X receptor, a key regulator of inflammatory, bile acid, metabolic, and fibrotic pathways. In addition, Intercept launched a comprehensive patient support program called Interconnect®, which provides custom support through care coordinators to patients requiring treatment support, disease education, and financial assistance options.

The team at Intercept Pharmaceuticals is comprised of dedicated, smart, hard-working professionals eager to achieve meaningful success, and the company is always looking to hire top talent. Benefits offered to eligible employees include insurance options, competitive pay, family support, retirement benefits, tuition reimbursement, and commuter benefits. Full-time, telecommute positions are offered to qualified candidates seeking work flexibility.